Science and Research

GATHER2: A Phase 3 Multicenter, Randomized, Double-Masked, Sham-controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

A Phase 3 safety and efficacy study of intravitreal administration of Zimura (Complement C5 Inhibitor).


The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD).

  • Principal Investigator
Dr Thanh Nguyen

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.